1. Home
  2. RPC vs VOR Comparison

RPC vs VOR Comparison

Compare RPC & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ridgepost Capital Inc. Class A Common Stock

RPC

Ridgepost Capital Inc. Class A Common Stock

N/A

Current Price

$8.72

Market Cap

932.7M

Sector

Finance

ML Signal

N/A

Logo Vor Biopharma Inc.

VOR

Vor Biopharma Inc.

HOLD

Current Price

$16.64

Market Cap

917.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RPC
VOR
Founded
1992
2015
Country
United States
United States
Employees
267
76
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
932.7M
917.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RPC
VOR
Price
$8.72
$16.64
Analyst Decision
Buy
Buy
Analyst Count
1
10
Target Price
$11.00
$45.33
AVG Volume (30 Days)
510.2K
880.2K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
1.96%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$16.82
N/A
Revenue Next Year
$15.80
N/A
P/E Ratio
$53.06
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.79
$0.15
52 Week High
$9.32
$49.95

Technical Indicators

Market Signals
Indicator
RPC
VOR
Relative Strength Index (RSI) 70.48 61.17
Support Level $6.94 $11.74
Resistance Level N/A $16.87
Average True Range (ATR) 0.32 0.92
MACD 0.09 0.19
Stochastic Oscillator 89.78 86.61

Price Performance

Historical Comparison
RPC
VOR

About RPC Ridgepost Capital Inc. Class A Common Stock

Ridgepost Capital Inc, formelrly P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.

About VOR Vor Biopharma Inc.

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

Share on Social Networks: